| |
Reception
of participant : 8:00am
Welcome speech by
- Claude FEUERSTEIN, President ADEBAG
- Silvano FUMERO, Vice-President BioIndustry Park
- Philippe SORDET, President BioAlps
- Jürgen SAUTTER, Scientific Officer for Neuroscience,
DG RTD - Health Directorate, European Commission |
Plenary
Opening Session (09:00am to 10:00am) :
- Dr. Graeme BILBE, Head of Nervous system Research,
Novartis Pharma AG.
Therapies for Nervous System Disorders
:
the Opportunities and the Challenges
|
:: Coffee
break :: 10:15am to 10:30am
|
| :: MORNING :: 10:30am
to 12:30am |
Brokerage
event
Click here |
Session
1 : Neuro Imaging
Chairman : Pr. Johan LUTHMAN, Head of Neuroscience,
Serono International |
- Pr. Christian
SPENGER : Experimental MR Research Center,
Karolinska Institute
Magnetic resonance
imaging and spectroscopy biomarkers in transgenic
mouse models
- Dr. Liqun WANG : Executive Director,
Global Head of Imaging, Biomarker Development, Exploratory
Development, Novartis Pharmaceuticals
Molecular neuroimaging
technologies to enhance CNS drug development
- Yves PATOUX : VP, Sales Director,
Isis-Robotics, Grenoble
Use of neuro-imaging
for navigated brain surgery
- Pr. Silvio AIME : Chemical Department,
University of Turino
Responsive MR agents
for Neuroimaging applications
::
Details :: |
Session
2 : Value of "-omics" in neuroscience
Chairman : Pr. Mauro FASANO, Centre of Neuroscience,
University of Insubria |
- Dr. Abderrahim
HADI : Serono Pharmaceuticals, Geneva
The genetic basis of
autoimmune diseases
- Dr. Massimo ALESSIO : Scientific
institute “San Raffaele Hospital” Milano
Proteomics analysis
of CSF from neurological disorders and development
of related computational methods
- Dr. Laure ALLARD : bioMérieux
S.A., Proteomics and Immunoassays R&D Department
Tools for bridging the gap between brain damage marker
discovery and the diagnosis of ischemic stroke patients
::
Details ::
|
|
Lunch
00:30pm to 02:30pm |
|
| ::
AFTERNOON :: 02:30pm to 05:00pm |
Brokerage
event
Click here |
Session
3 : Ageing and dementia
Chairman : Pr. Andrea Pfeifer, C.E.O, AC
Immune SA |
- Dr. Daniel
SAUMIER : Scientific Advisor, Drug Development
Department, Neurochem Inc.
Tramiprosate (Alzhemed
TM): a potential treatment for
Alzheimer’s disease
- Prof. Panteleimon GIANNAKOPOULOS
: Department of Psychiatry Research, HUG, Geneva
Predicting cognitive
decline in the elderly: from neuropathological markers
to functional parameters
- Dr. Andreas PAPASSOTIROPOULOS
: Division of Psychiatry Research, University of Zurich
Clinical and genetic
aspects of Alzheimer’s disease
- Prof. Hilal LASHUEL: Laboratoire
de Neurobiologie Moléculaire et Neuroprotéomique,
Ecole Polytechnique Fédérale de Lausanne
Protein Fibrillogenesis
in Parkinson's and Alzheimer's disease: from Biophysics
to therapeutic Strategies
- Pascal NEUVILLE, PhD : C.S.O FaustPharmaceuticals
SA, Illkirch
Glutamate hypothesis
for neurodegenerative diseases: time for a second
wind?
::
Details ::
|
Session
4 : New breakthrough therapies
Chairman : Pr. Claude FEUERSTEIN, Grenoble
Neuroscience Institute, Joseph Fourier University |
- Dr. Patricia
SALVATI : VP Discovery, Newron Pharmaceuticals
SpA, Italy
Safinamide: an innovative
treatment for Parkinson's Disease and Restless Leg
Syndrome
- Dr. Didier COQUOZ : C.E.O, Xigen
S.A
The challenge of successfully
evolving from academy to the biopharmaceutical industry.
Xigen S.A. a case story
- Nicole DEGLON : Unité d'imagerie
isotopique, biochimique et pharmacologique-Programme
Imagène CEA
Treatment of Neurodegenerative
diseases: from cell transplantation to gene therapy
- Pr. Pierre POLLAK : Unité
de Pathologie du Mouvement, Centre Hospitalier Universitaire
de Grenoble
Deep Brain Stimulation:
a new therapeutical concept
- Frédéric EBERLE
: Biological Physician, Head of Roche Diagnostics
Clinical use of DNA microarrays
for personalized neurotropic and psychotropic drugs
::
Details :: |
|
| Conclusive
Session (05:00pm to 06:00pm)
- Fulvio UGGERI, Director, Milano Research
Centre, Bracco Imaging
- Hervé PERRON, Senior Director Neurological diseases
Unit, bioMérieux
- Andrea PFEIFER, C.E.O., AC Immune SA
|
Closing
cocktail : Poster Session AWARDS (06:00pm) |
4,3Mo |
|
|
